

## OrthoAccel Technologies, Inc. and TOC Sign Distribution Agreement for United Kingdom

Houston, TX, April 14, 2011

**OrthoAccel® Technologies, Inc.** announced this week that it has entered into an exclusive agreement with **TOC** for distribution of the **AcceleDent™ System**. TOC is a well-recognized, market-leading orthodontic supply company focused on doctors in the UK and Ireland.

**AcceleDent**, an acceleration device to enhance orthodontics, was introduced to the United Kingdom in 2009. Results from the first clinical trial were published in **Orthodontic Practice US** in April 2010.

Mike Kaufman, VP Marketing and Business Development at OrthoAccel, noted the importance of the agreement with TOC and the Company's strategic plans for expansion. "The United Kingdom and Ireland represent the first markets where AcceleDent was introduced. Acceptance has been steadily increasing and we are confident that TOC will accelerate the brand awareness and adoption rate using their very experienced sales force. Our goal is for AcceleDent to become part of the standard of care for orthodontic treatment."

Martin Ingham, Co-Founder and Director of **TOC**, who has extensive experience in the orthodontic industry, commented "we are excited about our new relationship with OrthoAccel, we have always been associated with innovation and the AcceleDent System provides the orthodontist with a valuable new tool to advance the science of orthodontics. The length of treatment time has always been an area where the patient becomes frustrated. Using the AcceleDent System potentially provides a significant reduction in time leaving both the patient and orthodontist more satisfied with the overall orthodontic experience. The TOC team looks forward to introducing AcceleDent to the profession during 2011."

Earlier this month, AcceleDent was recognized with a **MDEA Award for the 14<sup>th</sup> Annual Medical Design Excellence Award**. Other winners include RelyX Luting Plus cement by 3M and the Waterlase MD dental therapy laser by BioLase.

OrthoAccel recently completed a randomized controlled clinical trial on 45 patients at the **UT Health Science Center in San Antonio**. Results demonstrate that 20 minutes of daily use with AcceleDent, as a complement to orthodontic braces, can increase the rate of tooth movement during the alignment phase by 106% and 38% during space closure. **Results** were statistically significant. An application was filed with the Food and Drug Administration (FDA) and Health Protection Branch (HPB) to permit sales in the USA and Canada, respectively. These key regulatory clearances are anticipated later this year.

### About OrthoAccel Technologies, Inc.

Based in Houston, Texas, **OrthoAccel Technologies, Inc.** is a privately owned medical device company currently engaged in the development, manufacturing, and marketing of products to enhance dental care and orthodontic treatment.

### About TOC

**TOC** was established in 1992 as an orthodontic supplies company serving the needs of the United Kingdom's orthodontic profession. With a distribution center in Bristol and one of the largest independent sales teams in the UK TOC supplies such leading brands as Dentsply GAC and Ortho Technology.

### About the AcceleDent System

**AcceleDent** represents the first clinical approach to safely accelerate orthodontic tooth movement via modulating biology. The device has been studied clinically and applies gentle pulsing forces in combination with standard orthodontics to move teeth faster through accelerated bone remodeling. Importantly, the device works complementary with all existing orthodontic technologies. **AcceleDent** is neither FDA cleared nor FDA approved; it is currently investigational only in the United States. More information can be found at [www.acceledent.com](http://www.acceledent.com) and [www.acceledent.co.uk](http://www.acceledent.co.uk) or requested via [info@orthoaccel.com](mailto:info@orthoaccel.com).